| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NY-SAR-48 |
| Uniprot No | Q9BT25 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-410 aa |
| 活性数据 | ADSSGRGAG KPATGPTNSS SAKKKDKRVQ GGRVIESRYL QYEKKTTQKA PAGDGSQTRG KMSEGGRKSS LLQKSKADSS GVGKGDLQST LLEGHGTAPP DLDLSAINDK SIVKKTPQLA KTISKKPEST SFSAPRKKSP DLSEAMEMME SQTLLLTLLS VKMENNLAEF ERRAEKNLLI MCKEKEKLQK KAHELKRRLL LSQRKRELAD VLDAQIEMLS PFEAVATRFK EQYRTFATAL DTTRHELPVR SIHLEGDGQQ LLDALQHELV TTQRLLGELD VGDSEENVQV LDLLSELKDV TAKKDLELRR SFAQVLELSA EASKEAALAN QEVWEETQGM APPSRWYFNQ DSACRESGGA PKNTPLSEDD NPGASSAPAQ ATFISPSEDF SSSSQAEVPP SLSRSGRDLS |
| 分子量 | 44.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于您提到的“重组人(NY-SAR-48)蛋白”，目前公开的科研文献中暂未找到该蛋白名称的明确研究记录(可能名称有误或属于未公开发表的新发现)。以下提供几篇类似主题的肿瘤相关抗原及重组蛋白研究的**示例参考文献**供参考：
---
1. **文献名称**：**"Identification of NY-ESO-1 as a shared cancer/testis antigen in diverse tumors"**
**作者**：Chen, Y. T., et al.
**摘要**：报道NY-ESO-1作为广泛表达的癌症/睾丸抗原，在多种肿瘤中特异性表达，可能用于癌症免疫治疗的靶点研究。
---
2. **文献名称**：**"Recombinant protein production in Escherichia coli: advances and challenges"**
**作者**：Rosano, G. L., & Ceccarelli, E. A.
**摘要**：综述大肠杆菌表达系统在重组蛋白生产中的优化策略(如载体设计、纯化技术)，适用于类似NY-SAR-48的重组蛋白制备。
---
3. **文献名称**：**"Cancer-associated retroviral antigens as targets for immunotherapy"**
**作者**：Smith, R. P., & Dudley, M. E.
**摘要**：探讨反转录病毒相关抗原(如SAR家族蛋白)在肿瘤中的表达及其诱导抗肿瘤免疫反应的潜力。
---
**建议**：若需精确文献，请核实蛋白名称的正确性(如是否混淆“NY-ESO-1”“SAR-35”等已知抗原)，或补充更具体的研究背景(如应用领域)。您可尝试在PubMed或Google Scholar中使用相关关键词(“NY-SAR-48 recombinant protein”)进行检索。
**Background of Recombinant Human NY-SAR-48 Protein**
NY-SAR-48. a cancer/testis (CT) antigen, is encoded by the *CT48* gene located on the X chromosome. It belongs to a family of proteins typically expressed in germ cells but aberrantly reactivated in various malignancies, making it a potential target for cancer immunotherapy. Initially identified through serological analysis of recombinant cDNA expression libraries (SEREX), NY-SAR-48 shares characteristics with other CT antigens, such as restricted expression in normal tissues (e.g., testis) and overexpression in cancers like melanoma, sarcoma, and carcinomas.
The recombinant NY-SAR-48 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. Structurally, it may contain functional domains implicated in protein-protein interactions or immune modulation, though its precise biological role remains under investigation. Studies suggest it could contribute to tumor progression by evading immune surveillance or promoting cell proliferation.
Clinically, NY-SAR-48 is explored as a biomarker for cancer diagnosis and a candidate for therapeutic vaccines or adoptive T-cell therapies. Its immunogenicity and tumor-specific expression enhance its appeal for targeting with minimal off-tissue toxicity. However, challenges include understanding its regulatory mechanisms, heterogeneity across cancers, and optimizing delivery systems for immunotherapy. Ongoing research aims to validate its functional significance and translational potential in precision oncology.
×
